A disorder that's still not fully understood
Schizophrenia affects about 1 in 300 people worldwide and is one of the most disabling psychiatric conditions known. It causes hallucinations, delusions, disorganized thinking, and a flattening of emotional expression. Even with treatment, outcomes vary enormously. Some people stabilize well. Others experience repeated hospitalizations, persistent symptoms, and significant cognitive decline.
Doctors currently have no blood test to guide treatment decisions in schizophrenia. Everything is based on observation, symptom rating scales, and clinical judgment. That makes personalized treatment extremely difficult.
What we thought we knew about the immune system
For decades, schizophrenia was understood primarily as a brain disorder — a problem with dopamine signaling, not with the immune system. Antipsychotic medications work by blocking certain dopamine receptors, and that has been the backbone of treatment for over 60 years.
But here's the twist: a growing body of research has found signs of immune system dysfunction in many people with schizophrenia. Higher rates of certain inflammatory proteins. Abnormal immune cell activity. And now, altered levels of complement proteins — part of the body's ancient first-line defense system.
The complement system — your body's first alarm
Think of the complement system as a burglar alarm for your immune system. When it senses a foreign invader — a virus, bacterium, or damaged cell — it activates a rapid cascade of proteins labeled C1 through C9. Two of the most important are C3 and C4.
C3 and C4 help tag threats so that immune cells can destroy them. But if the alarm is constantly going off when it shouldn't — triggered by the body's own brain cells — the resulting inflammation could damage neural connections over time. This is one of the leading theories for why complement proteins may matter in schizophrenia.
What the researchers measured
This study enrolled 39 patients with schizophrenia who were assessed at hospital admission. Researchers measured blood levels of C3 and C4 and then compared those levels to a battery of clinical assessments: symptom severity using the Positive and Negative Syndrome Scale (PANSS), anxiety levels, cognitive function using the Montreal Cognitive Assessment, and history of childhood trauma.
They also tracked patients for 12 weeks to see whether complement levels at admission related to how symptoms changed over time.
Patterns that stood out
Higher C3 levels at admission were linked to more severe positive symptoms (like delusions and hallucinations), greater anxiety, worse cognitive scores, and longer duration of untreated psychosis — meaning patients whose illness had gone unaddressed for longer tended to have higher C3.
C4 showed similar patterns, correlating with symptom severity at multiple time points over the 12-week follow-up period.
These are intriguing patterns — but the study's authors are clear that they must be treated with caution.
When the researchers applied a standard statistical correction called the Benjamini-Hochberg false discovery rate adjustment — designed to reduce the risk of finding false positives in small studies — none of the associations survived. This is a critical detail. It means the findings could reflect chance, not a true biological relationship.
Where this fits in the bigger picture
Despite the statistical limitations, this research is consistent with a larger wave of evidence linking complement biology to psychiatric illness. Separate genetic studies have found that variants in the C4 gene are among the strongest known genetic risk factors for schizophrenia. That genetic evidence provides a plausible biological mechanism for why blood levels of these proteins might correlate with symptom patterns.
For patients and families living with schizophrenia, this research is not something to act on right now. No complement-based blood test for schizophrenia is clinically available, and current treatment decisions should remain guided by experienced psychiatric care. What this research does offer is a direction — toward understanding why some people with schizophrenia have more severe or treatment-resistant illness than others. That understanding could eventually lead to better-targeted treatments.
This study included only 39 patients — far too few to draw firm conclusions. It was conducted at a single site without a healthy comparison group, making it impossible to know whether complement levels were truly different from what would be expected in the general population. The analyses were exploratory, and the authors themselves note that results did not survive correction for multiple comparisons. This study should be understood as hypothesis-generating, not confirmatory.
The authors call for replication in larger, longitudinal studies — ideally ones that include both patients and healthy controls, measure complement levels at multiple time points, and track treatment response over years, not weeks. If larger studies confirm these associations, researchers could move toward testing whether complement-targeting therapies (some of which already exist for other diseases) might benefit a subset of patients with schizophrenia. That is still a long road, but one that is increasingly worth mapping.
